阿托伐他汀对急性冠状动脉综合征患者血清hs-CRP水平的影响

目的探讨不同剂量阿托伐他汀治疗对急性冠状动脉综合征(ACS)患者血清高敏C反应蛋白(hs-CRP)的影响。方法选择广州军区武汉总医院2010年5月至2012年5月收治的122例ACS患者,将其随机分为阿托伐他汀强化组(40mg/d,41例)和阿托伐他汀治疗组(20mg/d,41例),对照组(常规硝酸酯类、血管紧张素转化酶抑制剂或β受体阻滞剂药物治疗,40例),分别在入院24h内及2周后测定3组患者血清hs-CRP水平,并进行比较。结果治疗2周后,3组患者血清hs-CRP水平较治疗前明显降低(P<0.05),阿托伐他汀治疗组hs-CRP水平较对照组明显降低(P<0.05),阿托伐他汀强化组hs-CRP水平较阿托伐他汀治疗组及对照组显著降低(P<0.05)。结论阿托伐他汀可以减少ACS患者动脉粥样硬化斑块的炎性反应,大剂量阿托伐他汀较常规剂量更能降低ACS患者的hs-CRP水平。

Effects of atorvastatin on serum high-sensitivity c-reactive protein level in patients with acute coronary syndrome

Objective To explore effects of atorvastatin with different doses on serum high-sensitivity c-reactive protein（hs-CRP） in patients with acute coronary syndrome（ACS）.Methods 122 patients with ACS in Wuhan General Hospital of Guangzhou Military from May 2010 to May 2012 were randomly divided into atorvastatin strength group（40 mg/d,n=41）,atorvastatin treatment group（20 mg/d,n=41）,and control group（taking nitrate and angiotensin converting enzyme inhibitors or beta blockers conventional treatment,n=40）.Serum hs-CRP levels of the three groups were measured and compared within 24 h after admission and 2 weeks after therapy.Results After 2 weeks treatment,the 3 group′s serum hs-CRP levels were apparently decreased compared with before treatment（P0.05）,in which,in terms of serum hs-CRP level,atorvastatin treatment group was significantly decreased than control group（P0.05）,atorvastatin strength group was significantly decreased than atorvastatin treatment group and control group（P0.05）.Conclusion Atorvastatin could reduce inflammatory reaction of atherosclerotic plaque in ACS patients,and taking large dose of atorvastatin could decrease hs-CRP level.